Physician profile
Daniel Ramirez
NPI 1720097512
$3,141.42
in general payments reported to CMS, 2019-2025
14 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $179 · 2023: $163 · 2024: $1,183 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,592.04 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $458.67 | 2021-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $193.54 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $178.29 | 2024-2025 | |
| Abbott Laboratories | $170.01 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $169.22 | 2024-2025 | Repatha, Otezla, Otezla |
| Redhill Biopharma INC. | $141.80 | 2021 | |
| Abbvie INC. | $78.43 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $38.38 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $26.89 | 2025 | |
| Dexcom, INC. | $24.92 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $23.50 | 2024 | Arexvy |
| Avanir Pharmaceuticals, INC. | $23.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.